Dosimetry for 90Y-DOTATOC therapies in patients with neuroendocrine tumors

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 1, 2007, Pages 130-135

  Hindorf, Cecilia ^a,c   Chittenden, Sarah ^a   Causer, Louise ^a   Lewington, Val J ^a   Mäcke, Helmut R ^b   Flux, Glenn D ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

90Y DOTATOC; Dosimetry; Neuroendocrine tumors; Treatment planning

Indexed keywords

AMINO ACID; DOTATOC IN 111; DOTATOC Y 90; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; CANCER PATIENT; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; DOSIMETRY; FEMALE; HUMAN; KIDNEY; MALE; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RENAL PROTECTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR; WHOLE BODY IMAGING; WHOLE BODY PET;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; RADIOMETRY; YTTRIUM RADIOISOTOPES;

EID: 34247886025     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.306     Document Type: Conference Paper

References (14)

1. Lewington VJ. Targeted radionuclide therapy for neuroendocrine tumors. Endocrine-Related Cancer 2003;10:497.
2. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations. New York: The Society of Nuclear Medicine, 1991.
3. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys 2003;85:294.
4. Cremonesi M, Ferrari M, Zoboli S, et al. Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: Implications for internal radiotherapy with (9)Y-DOTATOC. Eur J Nucl Med 1999;26:877.
5. Förster GJ, Engelbach M, Brockmann J, et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumors: Comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide. Eur J Nucl Med Mol Imag 2001;28:1743.
6. Forrer F, Uusijärvi H, Waldherr C, et al. A comparison of (111)In-DOTATOC and (111)In-DOTATE: Biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumors. Eur J Nucl Mol Imag 2004;31:1257.
7. Heiisch A, Förster GJ, Reber H, et al. Pre-therapeutic dosimetry and biodistritubion of 86 Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2004;31:1386.
8. Barone R, Borson-Chazot F, Valkema R, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46:99S.
9. Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials. J Nucl Med 2003;44:465.
10. Wiseman GA, Leigh BR, Erwin WD, et al. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 2003;18:165.
11. Lashford LS, Lewis IJ, Fielding SL, et al. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: A United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 1992;10:1889.
12. Matthay KK, Panina C, Huberty J, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 2001;42:1713.
13. Wahl RL, Kroll S, Zasadny KR. Patient-specific wholebody dosimetry: Principles and a simplified method for clinical implementation. J Nucl Med 1998;39:14S.
14. Wahl RL. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I131 tositumomab. Semin Oncol 2003;30:31.